Investment Rating - The investment rating for the company is "Outperform" (Maintain) [2] Core Views - The company is positioned as a high-elasticity player in the egg cycle, with growth driven by international expansion and lysozyme projects [2] - The company anticipates a significant increase in net profit for 2025, projecting a range of 80 million to 92 million yuan, representing a year-on-year growth of 75.44% to 101.75% [2] - The report highlights the successful launch of the Sichuan Oufu processing base, which enhances the company's supply chain capabilities and product gross margins due to declining raw egg prices [3] - The international egg price surge in 2025 presents an opportunity for the company to expand its overseas market presence, with successful exports of its lysozyme project contributing to new profit growth [4] Financial Summary - The company expects revenue to grow from 906 million yuan in 2024 to 1.131 billion yuan in 2025, reflecting a year-on-year increase of 24.8% [6] - The projected net profit for 2025 is 84 million yuan, up from 46 million yuan in 2024, indicating an 84.3% year-on-year growth [6] - Gross margin is expected to improve from 16.6% in 2024 to 18.2% in 2025, while net margin is projected to rise from 5.0% to 7.4% [6][9] - The company's earnings per share (EPS) is forecasted to increase from 0.22 yuan in 2024 to 0.41 yuan in 2025, with a corresponding price-to-earnings (P/E) ratio decreasing from 49.3 to 26.7 [6]
欧福蛋业：蛋周期高弹性标的，出海与溶菌酶构成增长双引擎-20260128